Q1 2019 13F Holders as of 3/31/2019
-
Type / Class
-
Equity / PHARMACEUTCL ETF
-
Number of holders
-
43
-
Total 13F shares, excl. options
-
1M
-
Shares change
-
-558K
-
Total reported value, excl. options
-
$60.8M
-
Value change
-
-$33.9M
-
Put/Call ratio
-
0.34
-
Number of buys
-
15
-
Number of sells
-
-18
-
Price
-
$60.70
Significant Holders of VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) as of Q1 2019
50 filings reported holding PPH - VANECK ETF TRUST - PHARMACEUTCL ETF as of Q1 2019.
VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) has 43 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1M shares
.
Largest 10 shareholders include GOLDMAN SACHS GROUP INC (450K shares), CLS Investments, LLC (247K shares), BANK OF AMERICA CORP /DE/ (55.4K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (25.4K shares), MORGAN STANLEY (25.1K shares), ROYAL BANK OF CANADA (24.2K shares), CITADEL ADVISORS LLC (22.8K shares), Cerity Partners LLC (21.4K shares), LPL Financial LLC (14.2K shares), and OPPENHEIMER & CO INC (13.7K shares).
This table shows the top 43 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.